|
|
|
|
|
 HTML
PDF |
|
Kozuch PL, Hanauer SB.Treatment of inflammatory bowel disease: A review of
medical therapy.
World J Gastroenterol 2008 January;14(3):354-377
Treatment of inflammatory bowel disease: A review of
medical therapy
Kozuch PL, Hanauer SB.
Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, 5841 S. Maryland Ave., MC 4076 Chicago, IL 60637, United States. shanauer@uchicago.edu
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater. Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non-systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD. Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC. |
|
|
|
The WJG Press, Room 1066, Yishou Garden ,
No. 58, North Langxinzhuang Road,
PO Box 2345, Beijing 100023, China
Fax: +86-10-85381893
Telephone: +86-10-85381892
E-mail: wjg@wjgnet.com
http: // www.wjgnet.com
Copyright 2004-2007 by The WJG Press and Beijing Baishideng BioMed Technology Co., Ltd.
| |
Editorial Board
